 |
 |
June 16, 2003 NeuroSearch A/S, of Bailerup, Denmark, and Boehringer Ingelheim GmbH, of Ingelheim, Germany, initiated a Phase II trial with NS2330 in recently diagnosed Parkinson's patients in the U.S. The study is a placebo-controlled, multicenter study enrolling about 250 patients. The study is expected to be completed in the second half of 2004 REFERENCE: NeuroSearch http://www.neurosearch.com/index2.php Boehringer Ingelheim http://www.boehringer-ingelheim.com/corporate/home/home.asp 16 June 2003 NEWS: Full Story NeuroSearch and Boehringer Ingelheim initiate a Phase II clinical study in the US with NS2330 for the treatment of early Parkinson`s disease http://www.mediconvalley.com/news/Article.asp?NewsID=405 8 February 2002 NeuroSearch (NEUS.CO) and Boehringer Ingelheim have signed an agreement for the development and marketing of NS2330 for the treatment of Alzheimer's disease and Parkinson's disease. http://www.noonanrusso.com/news/neurosearch/02news/neuro02.08.html SOURCE: Hoovers http://hoovnews.hoovers.com/fp.asp?layout=displaynews&doc_id=NR200306173000.2_2f5f01e3d3814940 * * * COMMENT: This one looks promising... murray ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn